Holen Sie sich die Stockscreener-App
124.92
0.47%
0.59
Handel nachbörslich:
124.00
-0.92
-0.74%
Schlusskurs vom Vortag:
$124.33
Offen:
$127.26
24-Stunden-Volumen:
1.24M
Relative Volume:
0.65
Marktkapitalisierung:
$10.89B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-386.19M
KGV:
-23.77
EPS:
-5.2547
Netto-Cashflow:
$-206.27M
1W Leistung:
-0.62%
1M Leistung:
-6.26%
6M Leistung:
+12.39%
1J Leistung:
+74.06%
1-Tages-Spanne:
$120.62
$127.51
1-Wochen-Bereich:
$118.18
$130.00
52-Wochen-Spanne:
$67.09
$148.83
Abivax Adr Stock (ABVX) Company Profile
Compare ABVX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
124.92 | 11.16B | 0 | -386.19M | -206.27M | -5.2547 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Eingeleitet | Jefferies | Buy |
| 2026-02-24 | Eingeleitet | Wedbush | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-06 | Eingeleitet | Wolfe Research | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-07-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-12-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | Laidlaw | Buy |
| 2024-05-20 | Eingeleitet | BTIG Research | Buy |
| 2024-04-29 | Eingeleitet | Guggenheim | Buy |
| 2024-04-29 | Eingeleitet | Piper Sandler | Overweight |
| 2023-11-14 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Abivax Adr Aktie (ABVX) Neueste Nachrichten
Eversept Partners LP Has $104.05 Million Holdings in Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax SA Sponsored ADR $ABVX Shares Sold by Octagon Capital Advisors LP - MarketBeat
Orbimed Advisors LLC Has $51.86 Million Holdings in Abivax SA Sponsored ADR $ABVX - MarketBeat
Hsbc Holdings PLC Has $1.71 Million Stock Holdings in Abivax SA Sponsored ADR $ABVX - MarketBeat
ABIVAX Société Anonyme (ABVX) stock price, news, quote and history - Yahoo Finance UK
ABIVAX Société Anonyme (ABVX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Caxton Associates LLP Acquires Shares of 24,750 Abivax SA Sponsored ADR $ABVX - MarketBeat
Affinity Asset Advisors LLC Has $45.10 Million Stake in Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax SA Sponsored ADR Revenue Breakdown – SWB:2X10 - TradingView
Abivax SA Sponsored ADR $ABVX Position Increased by PSquared Asset Management AG - MarketBeat
Atika Capital Management LLC Sells 26,200 Shares of Abivax SA Sponsored ADR $ABVX - MarketBeat
17,000 Shares in Abivax SA Sponsored ADR $ABVX Bought by Militia Capital Management LLC - MarketBeat
ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
Abivax SA Sponsored ADR $ABVX Shares Bought by Jennison Associates LLC - MarketBeat
Principal Financial Group Inc. Increases Holdings in Abivax SA Sponsored ADR $ABVX - MarketBeat
Brummer Multi Strategy AB Boosts Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
Diversify Wealth Management LLC Purchases 14,626 Shares of Abivax SA Sponsored ADR $ABVX - MarketBeat
Should you buy Abivax SA sponsored ADR (ABVX) after golden cross? - MSN
Candriam S.C.A. Takes $4.01 Million Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross? - Yahoo Finance
3 Soaring Stocks That May Have More Upside Ahead - The Motley Fool
2X10 Forecast — Price Target — Prediction for 2027 - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Abivax’s Hot Rally Is Suddenly Cooling Off - TipRanks
Weekly Recap: Upsized $920M ADS offering and Obefazimod UC results - TradingView
Pictet Asset Management Holding SA Reduces Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax SA Raises $760 Million in Major U.S. ADS Offering - TipRanks
Abivax Slides As Massive Stock Offering Spooks Traders - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why is Abivax stock climbing today? - Investing.com UK
Abivax stock surges on Phase 3 ulcerative colitis data By Investing.com - Investing.com Nigeria
Abivax Posts Positive Phase 3 Maintenance Data for Obefazimod in Refractory Ulcerative Colitis - TipRanks
Abivax Stock Slides as Phase 3 Update Disappoints - TipRanks
A3EWCP Forecast — Price Target — Prediction for 2027 - TradingView
Abivax SA sponsored ADR (ABVX) loses 41.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Abivax SA Sponsored ADR Actuals & Estimates (NASDAQ:ABVX) - TradingView
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai - Bitget
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Icon (ICLR) and Liquidia Technologies (LQDA) - The Globe and Mail
ABVX News | ABIVAX SA-ADR (NASDAQ:ABVX) - ChartMill
Abivax Soars As New Crohn’s Trial Ignites Hopes - TipRanks
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Guggenheim - The Globe and Mail
Barclays Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Finanzdaten der Abivax Adr-Aktie (ABVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):